Stay updated on Atezolizumab Subq in NSCLC: Clinical Trial
Sign up to get notified when there's something new on the Atezolizumab Subq in NSCLC: Clinical Trial page.

Latest updates to the Atezolizumab Subq in NSCLC: Clinical Trial page
- Check4 days agoChange DetectedLocations section expanded with additional regional locations (e.g., Rio Grande do Sul, São Paulo, Lombardy, Mexico City, Querétaro, Moscow Oblast, Niznij Novgorod, Respublika Mordoviya, Katerynoslav Governorate, Kharkiv Governorate) and a revision tag updated to v3.3.3. The older location groupings appear to have been replaced or reorganized.SummaryDifference0.7%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedExpanded the study's location list to 74 sites worldwide, adding new sites such as Ivano-Frankivsk Regional Oncology Center (Ukraine), Kaluga (Russia), Hospital Nossa Senhora da Conceicao (Brazil), ICESP (São Paulo, Brazil), Instituto do Cancer do Estado de Sao Paulo and others across Argentina, Chile, China, Mexico, Greece, New Zealand, Italy, and more. Several previously listed sites were removed.SummaryDifference3%

- Check32 days agoChange DetectedThe Publications section now notes that entries are automatically filled from PubMed and the page revision updated to v3.3.2, replacing the previous wording about PubMed-derived publications and revision v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange Detected- The government funding lapse notice has been removed from the page. The clinical trial details and study information appear unchanged.SummaryDifference0.2%

- Check54 days agoChange DetectedEnrollment updated to 438 and the last update date shown as 2025-06-12. The locations section appears expanded to include additional sites across multiple countries.SummaryDifference0.2%

- Check83 days agoChange DetectedUpdate includes a prominent operating-status notice and a version upgrade from v3.1.0 to v3.2.0. If no other content changes are present, this indicates readiness/maintenance rather than new features.SummaryDifference2%

Stay in the know with updates to Atezolizumab Subq in NSCLC: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Atezolizumab Subq in NSCLC: Clinical Trial page.